Microbial Contamination Controls That Prevent OTC Cream Recalls

A May 2026 recall of an eczema treatment cream contaminated with Staphylococcus aureus is a good reminder of what happens when microbial controls fall short — and what manufacturers can do to make sure it doesn't happen to them.

When Pharmacal recalled one lot of MG217 Multi-Symptom Treatment Cream & Skin Protectant Eczema Cream in May 2026 due to Staphylococcus aureus contamination, the headline was about the product. But the more important story is upstream — in the quality systems, testing protocols, and manufacturing controls that either catch contamination before product ships or allow it to slip through.

Topical OTC products intended for use on compromised skin — eczema, psoriasis, dry and cracked skin — carry a higher contamination risk than most manufacturers appreciate. The patients using these products often have broken skin barriers, which means a contaminated cream isn't just a quality failure. It's a direct pathway for a serious opportunistic pathogen to enter the body.

In my experience working with OTC manufacturers and pharmaceutical clients, microbial contamination issues rarely trace back to a single dramatic failure. They trace back to a slow accumulation of small gaps — in water system monitoring, preservative qualification, environmental controls, or finished product testing. Any one of those gaps, on the wrong day, produces exactly the kind of recall we saw in May 2026.

Here's what good microbial controls actually look like, and where I most often see manufacturers come up short.

Why Staphylococcus Aureus Is a Specific Regulatory Concern for Topical Products

Staphylococcus aureus is not just a manufacturing nuisance. It is an objectionable microorganism under the United States Pharmacopeia (USP) and a specific target under FDA's current Good Manufacturing Practice (cGMP) framework for non-sterile pharmaceuticals and OTC products.

USP <1111>, "Microbiological Examination of Nonsterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use," specifies that S. aureus must be absent in 1 gram or 1 mL of product for most topical preparations. This is not a threshold — it's a zero-tolerance requirement. Finding it in a finished lot means the product fails specification, period.

What makes S. aureus particularly problematic in topical creams is its resilience. It tolerates a wide range of pH levels, survives in moderate preservative concentrations, and forms biofilms on manufacturing surfaces that are difficult to eradicate with standard cleaning protocols. A 2021 review in the Journal of Hospital Infection found that S. aureus can survive on dry environmental surfaces for more than 90 days under typical ambient conditions — which means an inadequately controlled manufacturing environment can harbor and reintroduce the organism across multiple production runs.

For products marketed to people with eczema, the stakes are especially clear. Eczema patients frequently have S. aureus colonization on their skin already, and damaged skin barrier function means topical exposure can escalate to serious skin and soft tissue infections. The FDA has consistently flagged contaminated topical products intended for compromised skin as Class II recalls — products where there is a reasonable probability of adverse health consequences.

The Regulatory Framework: What cGMP Actually Requires

The governing regulation for OTC drug manufacturers is 21 CFR Part 211 — Current Good Manufacturing Practice for Finished Pharmaceuticals. The microbial control obligations are not tucked into an obscure corner of the regulation. They appear across multiple sections.

21 CFR 211.113 — Control of Microbiological Contamination requires that written procedures be established and followed to prevent objectionable microorganisms in non-sterile drug products. This includes process controls, in-process testing, and environmental monitoring. This clause is frequently cited in FDA warning letters when manufacturers lack adequate microbial control programs.

21 CFR 211.68 governs equipment used in manufacturing and requires that systems, including water systems, be routinely monitored. Purified Water systems that feed topical cream manufacturing are a common vector for microbial contamination and are a standard inspection target.

21 CFR 211.84 covers the testing and approval of components and drug product containers. Incoming raw material testing — including microbiological testing of water-phase ingredients — is required before use in manufacturing.

21 CFR 211.192 requires that any unexplained discrepancy or batch failure be thoroughly investigated before a decision on disposition is made. In plain terms: if your finished product testing finds a microbiological result outside specification, you investigate before you do anything with that lot.

Manufacturers of OTC products also need to understand FDA's Guidance for Industry on the Microbiological Quality of Non-Sterile Drug Products, which provides the agency's current thinking on objectionable organisms and acceptance criteria. That guidance aligns closely with USP <61> and <62> and makes clear that absence of S. aureus is a baseline expectation, not an elevated standard.

Where Microbial Control Programs Actually Break Down

I have helped more than 200 clients navigate FDA audits and build quality systems across pharmaceutical, medical device, and consumer health settings. When microbial contamination incidents come up — either in a recall, a warning letter, or a pre-approval inspection finding — they almost always connect to one or more of the following failure points.

Water System Monitoring That Isn't Actually Monitored

Purified Water is the most common single ingredient in topical cream formulations, and it is also the most common source of microbial contamination in non-sterile manufacturing. A water system that looks good on paper but isn't trending, alert-limiting, or action-limiting in practice is essentially an unmonitored system.

I regularly see manufacturers with Purified Water systems that meet USP <1231> specifications on paper but whose sampling logs show gaps of weeks or months, whose trend data has never been formally reviewed, and whose alert and action limits were set arbitrarily in the initial validation and never revisited. That system is a contamination risk that hasn't been noticed yet.

A well-designed water system monitoring program samples at multiple points of use, runs on a defined schedule, trends results against alert limits (not just action limits), and connects deviations to a formal investigation process. When the system starts drifting, you catch it before it ends up in your finished product.

Preservative Efficacy Testing Done Once and Never Revisited

Preservative efficacy testing (PET), conducted per USP <51>, is commonly performed at the time of formulation development and then treated as a permanent checkbox. In reality, preservative system effectiveness can be affected by raw material source changes, minor formulation tweaks, packaging changes, and storage condition variations. A formulation that passed PET three years ago with one supplier's raw materials may behave differently today.

For products intended for use on compromised skin, I would argue that preservative efficacy should be part of the ongoing stability program — not a one-time development activity. The FDA hasn't made PET re-testing a hard requirement for every formula change, but they have issued 483 observations where manufacturers couldn't demonstrate that their preservative system remained effective after changes that could plausibly affect it.

Environmental Monitoring Programs That Don't Cover the Right Areas

21 CFR 211.42 requires that manufacturing facilities be of appropriate design to prevent contamination. Environmental monitoring (EM) programs are the tool manufacturers use to verify that the facility is actually behaving the way the design intended.

A common gap I see: EM programs that sample surfaces but don't include air monitoring, or that sample at low-risk areas but miss the fill zone. S. aureus is primarily a human-origin organism — personnel are typically the introduction point. An EM program that doesn't monitor personnel hygiene compliance, gowning effectiveness, or the air above open product during filling is missing the most likely contamination vector.

Effective environmental monitoring for topical OTC manufacturing should include surface and air sampling in the manufacturing and filling areas, personnel monitoring (contact plates on gloved hands), trend analysis by location and organism type, and defined escalation procedures when indicator organisms appear.

Finished Product Release Testing That Relies on Sampling Gaps

USP <61> and <62> provide the testing methodology for microbial enumeration and detection of specified microorganisms. Most OTC manufacturers conduct finished product microbial testing before release. The failure mode isn't usually that no testing is done — it's that the sampling plan doesn't provide adequate statistical confidence that a contaminated lot will be detected.

A lot-level contamination with S. aureus may not be homogeneous across every unit. If your sampling plan pulls only the minimum number of units required by your procedure, and those units happen not to be from the contaminated portion of the lot, you ship contaminated product with a passing test result. That's a sampling adequacy problem, and it's addressable through a statistically justified sampling plan tied to lot size and risk.

A Practical Framework: Microbial Control Across the Manufacturing Lifecycle

The table below maps the key control points against the regulatory requirements and the most common failure mode at each stage.

Every one of these control points represents a place where contamination can be caught before a product reaches a consumer. A recall happens when enough of these points fail simultaneously — or when the gaps overlap in just the wrong way.

What a Pre-Market Audit Would Have Caught

The Pharmacal MG217 recall affected one lot. That suggests the contamination was not systemic across the manufacturing process — but it also means the finished product release testing did not catch it before the lot shipped. That's the key gap.

When I conduct a quality systems audit for an OTC topical manufacturer, the microbial program is one of the first areas I examine. I look at the water system monitoring logs, the preservative efficacy data, the environmental monitoring trend reports, and the finished product testing records. If any of those four areas show gaps, I flag them — because any one of them can produce exactly the kind of single-lot contamination event that results in a recall and an FDA enforcement action.

For manufacturers who haven't had an independent quality audit recently, the May 2026 recall is a reasonable prompt to schedule one. A pre-market or periodic compliance audit is far less expensive than a recall — both financially and in terms of the brand trust that's difficult to rebuild once a product linked to a serious pathogen shows up on the FDA recall database.

A compliance review by an experienced consultant who knows where FDA inspectors look — and where the most common gaps appear in topical OTC manufacturing — can identify the control weaknesses before a regulator or a consumer does.

If you want to understand what that kind of audit looks like in practice, explore our pharmaceutical compliance consulting services at certify.consulting or review our approach to GMP audit preparation.

The Broader Pattern: Topical OTC Microbial Recalls Are Not Rare

The MG217 recall is not an outlier. FDA recall data shows that microbial contamination is one of the leading causes of Class II recalls for topical OTC drug products. Between 2018 and 2024, FDA announced more than 40 topical drug product recalls in which microbial contamination — including S. aureus, Pseudomonas aeruginosa, and Burkholderia cepacia — was cited as the reason. That's roughly one every two months across the industry.

Burkholderia cepacia, another organism that appears frequently in topical cream recalls, is particularly challenging because it can grow in preservative systems that are otherwise considered effective and can survive in dilute aqueous environments that many manufacturers don't treat as high-risk. Its appearance in a product typically signals a water system or raw material sourcing problem.

The pattern across these recalls is consistent: manufacturers with robust, actively managed microbial control programs don't appear on that list. The ones who do have gaps that — in retrospect — were identifiable and addressable before the contamination event.

Key Deadlines and Compliance Considerations for 2026

For manufacturers currently reviewing their microbial control programs in light of recent enforcement activity, a few current-context items are worth noting.

FDA's OTC Monograph reform under the CARES Act has brought increased scrutiny to OTC drug manufacturers who may have been operating under older compliance expectations. As of 2020, OTC drug manufacturers are subject to the same cGMP enforcement framework as prescription drug manufacturers, and FDA has indicated that it intends to increase inspection frequency for OTC facilities that had historically received less attention.

Manufacturers who have not had an FDA inspection in the past three years and who produce topical products for use on compromised skin — eczema, psoriasis, wound care, or diabetic skin care products — should treat the current regulatory environment as a prompt to conduct a voluntary internal audit or hire an external consultant to conduct one. The cost of prevention is predictable. The cost of a recall is not.

Frequently Asked Questions

See FAQ section below.

Last updated: 2026-05-31

Source reference: FDA Recall Notice — Pharmacal MG217 Multi-Symptom Treatment Cream